Pfizer COVID Vaccine for Younger Children Hits Snag
December 20, 2021
(Medscape) – Pfizer’s COVID-19 vaccine for children ages 2 to 5 years old fizzled in clinical trials, the company said on Friday, signaling a further delay in getting a vaccine to preschoolers just as Omicron bears down on the U.S. In a news release, Pfizer reported that while its 3-microgram dose — which is less than one-third of the dose given to older children — generated a protective immune response in babies and toddlers ages 6 to 24 months, it didn’t generate adequate immunity in children ages 2 to 5. (Read More)